Data Insights

Fosifloxuridine nafalbenamide by NuCana for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Gastric Cancer: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Gastric Cancer

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Metastatic Melanoma: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Metastatic Melanoma

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Endometrial Cancer: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Endometrial Cancer

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Esophageal Cancer: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Esophageal Cancer

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Metastatic Renal Cell Carcinoma

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Triple-Negative Breast Cancer (TNBC)

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

Fosifloxuridine nafalbenamide by NuCana for Metastatic Colorectal Cancer: Likelihood of Approval

Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Fosifloxuridine Nafalbenamide in Metastatic Colorectal Cancer